Characterization, thermodynamic parameters, molecular modeling and in vivo studies of inclusion complexes of pyrimethamine with native β-cyclodextrin and its derivatives

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 4, Issue 4, 2012, Pages 102-112

  Chadha, Renu ^a   Gupta, Sushma ^a   Pissurlenkar, Raghuvir R S ^b   Coutinho, Evans C ^b  

^a PANJAB UNIVERSITY   (India)

^b BOMBAY COLLEGE OF PHARMACY   (India)

Author keywords

cyclodextrins; Dissolution efficiency; In vivo studies; Inclusion complexes; Pyrimethamine; Stoichiometry

Indexed keywords

BETA CYCLODEXTRIN; CHLOROBENZENE; PYRIMETHAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; CALORIMETRY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG BINDING; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; ENERGY; ENTHALPY; FREEZE DRYING; INFRARED SPECTROSCOPY; MALARIA; MASS SPECTROMETRY; MOLECULAR MODEL; MOUSE; NANOENCAPSULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREDICTION; STOICHIOMETRY; THERMODYNAMICS;

EID: 84870918982     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Anderson AC. Targeting DHFR in parasitic protozoa. Drug Discovery Today 2005; 10:121-128.
2. Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MS, van Ruyven RL, Klok AM, Hoyng CB, Rothova A. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am J Ophthalmol 2002; 134:34-40.
3. The International Pharmacopoeia; Monograph pyrimethamine. 4th edition - 2006.
4. Haber RRG, Schoenberger E. Water-soluble composition comprising sulfadimidine and pyrimethamine; 1971. United States Patent 3728452.
5. Stolar E, Morris Tel Aviv. Water-soluble composition comprising sulfadimidine and pyrimethamine; 1977. United States Patent 4062940.
6. Ngouesse B, Basco LK, Ringwald P, Keundjian A, and Blackett KN. Cardiac effects of amodiaquine and sulfadoxinepyrimethamine in malaria-infected African patients. Am J Trop Med Hyg 2001; 65(6):711-716.
7. Elamin SB, Malik1 EM, Abdelgadir1 T, Khamiss AH, Mohammed MM, Ahmed ES and Adam I. Artesunate plus sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum malaria in Sudan. Malaria Journal 2005; 4(41):1-4. doi:10.1186/1475-2875-4-4.1
8. Figueiras A, Carvalho RA, Ribeiro L, Torres-Labandeira JJ, Veiga FJB. Solid-state characterization and dissolution characteristics on the inclusion complex of omeprazole with native and chemically modified β-cyclodextrin. Eur J Pharm Biopharm 2007; 67: 531-539.
9. Lokamatha K M, Bharathi A, Shanta Kumar S M, Rama Rao N. Effect of pvp-k30 on complexation and dissolution rate of nevirapine-β-cyclodextrin complexes. International Journal of Pharmacy and Pharmaceutical Science. 2010: 2(4):169-176.
10. Sinha VR, Anitha R, Ghosh S, Nanda A, Kumria R. Complexation of celecoxib with β-cyclodextrin: Characterization of the interaction in solution and in solid state. J Pharm Sci 2005; 94:676-687.
11. Mathew D. A study on suitability of nimesulide-beta cyclodextrin complex in oral and topical dosage forms. 2009; 2(1):193-198.
12. Plaizier-Vercammen, J, Gabriels M. Inclusion complexes of artemisnin or derivatives with cyclodextrins. Patent no. WO/2004075921. April, 2004.
13. Yang Bo, Lin J, Chen Y, Liu Y. Artemether/hydroxypropyl- β- cyclodextrin host-guest system: Characterisation, phase solubility and inclusion mode. Journal of Bioorganic & Medicinal Chemistry 2009; 17:311-6317.
14. Loftsson T, Hreinsdótir D, Máson M. Evaluation of cyclodextrin solubilization of drugs. International Journal of Pharmaceutics 2005; 302 (1-2):18-28.
15. Patel AR, Vavia PR. Effect of Hydrophilic Polymer on Solubilization of Fenofibrate by Cyclodextrin Complexation. Journal of Inclusion Phenomena and Macrocyclic Chemistry 2006; 56:247-251. DOI 10.1007/s10847-006-9091-4.
16. Mura P, Corti G, Maestrelli F, Cirri M. The influence of chitosan on cyclodextrin complexing and solubilizing abilities towards drugs. Journal of Inclusion Phenomena and Macrocyclic Chemistry 2007;59:307-313. DOI 10.1007/s10847-007-9329-9.
17. Loftsson T, Gumundsdottir TK, Fririksdottir H. The influence of water-soluble polymers and pH on hydroxypropyl-β-cyclodextrin complexation of drugs. Drug Dev Ind Pharm 1996; 22: 401-405.
18. Loftsson T and Brewster ME. Pharmaceutical Applications of Cyclodextrins. 1. Drug Solubilization and Stabilization. Journal of Pharmaceutical Sciences 1996; 85:1017-1025.
19. de Araujo MVG, Macedo OFL, Nascimento C da Cunha, Conegero LS, Barreto LS, Almeida LE, da Costa Jr NB, Gimenez IF. Characterization, phase solubility andmolecular modeling of α- cyclodextrin/pyrimethamine inclusion complex. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 2009; 72:165-170.
20. Onyeji CO, Omoruyi SI, Oladimeji FA, Soyinka JO. Physicochemical characterization and dissolution properties of binary systems of pyrimethamine and 2-hydroxypropyl-β- cyclodextrin. African Journal of Biotechnology 2009; 8(8):651-659.
21. de Araujo MVG, Vieira EKB, Lazaro GS, Conegero Ld.S, Ferreira OP, Almedia LE, Barreto LS, Gimenez NB, da Costa IF. Inclusion complexes of pyrimethamine in 2-hydroxypropyl- β- cyclodextrin: Characterisation, phase solubility and molecular modeling. J Bio Med Chem 2007; 15:5752-5759.
22. Higuchi T, Connors KA. Phase solubility techniques. Adv Anal Chem Instr 1965; 4:117-212.
23. McGann M, Almond H, Nicholls A, Grant JA, Brown F. Gaussian docking functions. Biopolymers. 2003; 68:76.
24. McGaughey GB, Sheridan RP, Bayly CI, Culberson JC, Kreatsoulas C, Lindsley S, Maiorov V, Truchon J-F, Cornell, WD. Comparison of topological, shape, and docking methods in virtual screening. J Chem Inf Model. 2007; 47:1504.
25. Berman HM et al. The Protein Data Bank. Nucleic Acids Res. 2000; 28:235-242.
26. Mark P, Nilsson, L. Structure and Dynamics of the TIP3P, SPC, and SPC/E Water Models at 298 K. J Phys Chem A 2001; 105:9954-9960.
27. Quigley D, Prober MIJ. Constant pressure Langevin dynamics: theory and application. Computer Physics Communications 169; 2005:322-325.
28. Ryckaert J-P, Ciccotti G, Berendsen HJC. Numerical integration of the cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes. J Comput Phys 1977; 23:327-341.
29. Kobetic R, Jursic BS, Bonnette S, Tsai S-C, Salvotore SJ. Study of the lorazepam: cyclodextrin inclusion complexes using electrospray ionization mass spectrometry. Tetrahedron Letters 2001; 42:6077-6082.
30. Cai Y, Tarr MA, Xu GX, Yalcin T, Cole RB. Studies of Cyclodextrin Inclusion Complexes by Electronic (UV-Vis Absorption and Emission) Spectroscopy. J Am Soc Mass Spectrum 2003; 14:449-459.
31. Job P. Recherches sur la formation de complexes mineraux en solution et sur leur stabilite. Ann Chem 1928; 9:1132-114.
32. Rodriguez-Perez AI, Rodriguez-Tenreiro C, Alavarez-Lorenzo C, Taboada P, Concheiro A, Torres-Labandeira JJ. Sertaconazole/Hydroxypropyl-β- cyclodextrin complexation: Isothermal Titration calorimetry and solubility approaches. Journal of Pharmaceutical Sciences 2006; 95:1751-1762.
33. Calderone CT, Williams DH. An enthalpy component in cooperativity: The relationship between enthalpy, entropy, and noncovalent structure in weak associations. J Am Chem Soc 2001; 123:6262-6267.
34. Tong WQ, Lach JL, Chin TF, Guillory JK. Microcalorimetric investigation of the complexation between hydroxypropyl-β- cyclodextrin and amine drugs with the diphenylmethyl functionality. J Pharm Biomed Anal 1991; 9:1139-1146.
35. Dunitz JD. Win some, lose some: enthalpy-entropy compensation in weak intermolecular interactions. Chem Biol 1995; 11:709-712.